{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:52:30Z","timestamp":1782125550663,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Perinatol"],"DOI":"10.1038\/s41372-026-02750-6","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:25:20Z","timestamp":1782123920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical utility of paracetamol serum concentration monitoring for patent ductus arteriosus treatment in preterm infants"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1443-1316","authenticated-orcid":false,"given":"Amira","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-7138","authenticated-orcid":false,"given":"Mahmoud","family":"Koritena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeria","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudasir","family":"Nazir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mcnulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Dabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-2977","authenticated-orcid":false,"given":"Mona","family":"Noureldein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2750_CR1","doi-asserted-by":"publisher","first-page":"e1618","DOI":"10.1542\/peds.2011-0359","volume":"128","author":"C Hammerman","year":"2011","unstructured":"Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011;128:e1618\u201321. https:\/\/doi.org\/10.1542\/peds.2011-0359.","journal-title":"Pediatrics"},{"key":"2750_CR2","doi-asserted-by":"publisher","unstructured":"Ohlsson A, Shah PS Paracetamol (acetaminophen) for patent ductus arteriosus in preterm and\/or low-birth-weight infants. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2012 [cited 2025 Dec 2]. p. CD010061. Available from: https:\/\/doi.org\/10.1002\/14651858.CD010061","DOI":"10.1002\/14651858.CD010061"},{"key":"2750_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.5863\/1551-6776-24.2.134","volume":"24","author":"C McPherson","year":"2019","unstructured":"McPherson C, Luecke CM, Liviskie CJ, Zeller BN, Vesoulis ZA. Acetaminophen serum concentrations in infants treated intravenously for patent ductus arteriosus. J Pediatr Pharm Ther. 2019;24:134\u20137. https:\/\/doi.org\/10.5863\/1551-6776-24.2.134.","journal-title":"J Pediatr Pharm Ther"},{"key":"2750_CR4","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/jcpt.13384","volume":"46","author":"K Sridharan","year":"2021","unstructured":"Sridharan K, Al Jufairi M, Al Ansari E, Al Marzooq R, Hubail Z, Hasan SJR, et al. Intravenous acetaminophen (at 15 mg\/kg\/dose every 6h) in critically ill preterm neonates with patent ductus arteriosus: A prospective study. J Clin Pharm Ther. 2021;46:1010\u20139. https:\/\/doi.org\/10.1111\/jcpt.13384.","journal-title":"J Clin Pharm Ther"},{"key":"2750_CR5","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41390-022-01944-w","volume":"92","author":"A Gover","year":"2022","unstructured":"Gover A, Levy PT, Rotschild A, Golzman M, Molad M, Lavie-Nevo K, et al. Oral versus intravenous paracetamol for patent ductus arteriosus closure in preterm infants. Pediatr Res. 2022;92:1146\u201352. https:\/\/doi.org\/10.1038\/s41390-022-01944-w.","journal-title":"Pediatr Res"},{"key":"2750_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41372-019-0347-4","volume":"39","author":"M Liebowitz","year":"2019","unstructured":"Liebowitz M, Kaempf J, Erdeve O, Bulbul A, H\u00e5kansson S, Lindqvist J, et al. Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). J Perinatol. 2019;39:599\u2013607. https:\/\/doi.org\/10.1038\/s41372-019-0347-4.","journal-title":"J Perinatol"},{"key":"2750_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jpeds.2016.04.066","volume":"177","author":"P H\u00e4rkin","year":"2016","unstructured":"H\u00e4rkin P, H\u00e4rm\u00e4 A, Aikio O, Valkama M, Leskinen M, Saarela T, et al. Paracetamol accelerates closure of the ductus arteriosus after premature birth: a randomized trial. J Pediatr. 2016;177:72\u201377.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2016.04.066.","journal-title":"J Pediatr"},{"key":"2750_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jpeds.2018.01.024","volume":"198","author":"A Bin-Nun","year":"2018","unstructured":"Bin-Nun A, Fink D, Mimouni FB, Algur N, Hammerman C. Paracetamol serum concentrations in neonates treated enterally for ductal closure: a pilot study. J Pediatr. 2018;198:304\u20137. https:\/\/doi.org\/10.1016\/j.jpeds.2018.01.024.","journal-title":"J Pediatr"},{"key":"2750_CR9","doi-asserted-by":"publisher","first-page":"e245406","DOI":"10.1136\/bcr-2021-245406","volume":"15","author":"K Raghu","year":"2022","unstructured":"Raghu K, Berry MJ. Acute liver failure secondary to therapeutic paracetamol dosing in an extremely preterm neonate. BMJ Case Rep. 2022;15:e245406 https:\/\/doi.org\/10.1136\/bcr-2021-245406.","journal-title":"BMJ Case Rep"},{"key":"2750_CR10","doi-asserted-by":"publisher","first-page":"407.1","DOI":"10.1136\/archdischild-2024-328436","volume":"110","author":"J Jeevahan","year":"2025","unstructured":"Jeevahan J, Koritena M, Ali A, Noureldein M. In preterm infants receiving paracetamol for patent ductus arteriosus (PDA) treatment, does monitoring serum paracetamol concentrations correlate with reduced risk of hepatotoxicity and improved rates of ductal closure? Arch Dis Child. 2025;110:407.1\u2013409. https:\/\/doi.org\/10.1136\/archdischild-2024-328436.","journal-title":"Arch Dis Child"},{"key":"2750_CR11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1080\/14767058.2020.1752652","volume":"35","author":"M Noureldein","year":"2022","unstructured":"Noureldein M, Hu K, Groucutt J, Heaver R, Gurusamy K. Paracetamol for patent ductus arteriosus in preterm infants: a UK national survey. J Matern-Fetal Neonatal Med. 2022;35:1408\u201311. https:\/\/doi.org\/10.1080\/14767058.2020.1752652.","journal-title":"J Matern-Fetal Neonatal Med"},{"key":"2750_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/chd.12727","volume":"14","author":"JL Shepherd","year":"2019","unstructured":"Shepherd JL, Noori S. What is a hemodynamically significant PDA in preterm infants? Congenit Heart Dis. 2019;14:21\u20136. https:\/\/doi.org\/10.1111\/chd.12727. PubMed PMID: 30548469.","journal-title":"Congenit Heart Dis"},{"key":"2750_CR13","unstructured":"Cambridge Life Sciences [Internet]. [cited 2025 Dec 4]. Therapeutic Drug Monitoring (Paracetamol or Salicylate). Available from: https:\/\/www.clsdiagnostics.com\/collections\/therapeutic-drug-monitoring-collection."},{"key":"2750_CR14","doi-asserted-by":"publisher","first-page":"F144","DOI":"10.1136\/adc.2008.152454","volume":"96","author":"S Victor","year":"2011","unstructured":"Victor S, Dickinson H, Turner MA. Plasma aminotransferase concentrations in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2011;96:F144\u20135. https:\/\/doi.org\/10.1136\/adc.2008.152454.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2750_CR15","doi-asserted-by":"publisher","first-page":":e84892","DOI":"10.1371\/journal.pone.0084892","volume":"8","author":"A Bruel","year":"2013","unstructured":"Bruel A, Roz\u00e9 JC, Flamant C, Simeoni U, Roussey-Kesler G, Allain-Launay E. Critical serum creatinine values in very preterm newborns. PLoS One. 2013;8::e84892 https:\/\/doi.org\/10.1371\/journal.pone.0084892.","journal-title":"PLoS One"},{"key":"2750_CR16","unstructured":"R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2024. Available from: https:\/\/www.r-project.org."},{"key":"2750_CR17","doi-asserted-by":"publisher","unstructured":"Jones KC, Weatherly H, Birch S, Castelli A, Chalkley M, Dargan A, et al. Unit Costs of Health and Social Care 2023 Manual [Reports and Papers] [Internet]. Kent, UK: Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York); 2024 [cited 2025 Dec 4]. Available from: https:\/\/doi.org\/10.22024\/UniKent\/01.02.105685.","DOI":"10.22024\/UniKent\/01.02.105685"},{"key":"2750_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40273-020-00979-3","volume":"39","author":"RA Vreman","year":"2021","unstructured":"Vreman RA, Geenen JW, Knies S, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG. The application and implications of novel deterministic sensitivity analysis methods. Pharmacoeconomics. 2021;39:1\u201317. https:\/\/doi.org\/10.1007\/s40273-020-00979-3.","journal-title":"Pharmacoeconomics"},{"key":"2750_CR19","unstructured":"Pay scales for 2025\/26 | NHS Employers [Internet]. [cited 2025 Dec 4]. Available from: https:\/\/www.nhsemployers.org\/articles\/pay-scales-202526."},{"key":"2750_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/children12060755","volume":"12","author":"S Gunes","year":"2025","unstructured":"Gunes S, Sahin S, Durmaz Engin C, Ergin F, Aldemir Sonmez A, Bozkurt \u00d6, et al. Association between patent ductus arteriosus and the development of treatment-requiring retinopathy of prematurity in preterm infants: a single-center cohort study. Child (Basel). 2025;12:755 https:\/\/doi.org\/10.3390\/children12060755.","journal-title":"Child (Basel)"},{"key":"2750_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1542\/peds.57.3.347","volume":"57","author":"B Siassi","year":"1976","unstructured":"Siassi B, Blanco C, Cabal LA, Coran AG. Incidence and clinical features of patent ductus arteriosus in low-birthweight infants: a prospective analysis of 150 consecutively born infants. Pediatrics. 1976;57:347\u201351.","journal-title":"Pediatrics"},{"key":"2750_CR22","doi-asserted-by":"publisher","unstructured":"Spenard S, Backes C, Fitzgerald DA, Sant\u2019Anna G, Altit G Current approaches to the patent ductus arteriosus: Implications for pulmonary morbidities. Paediatr Resp Rev. 2025;S1526054225000570. https:\/\/doi.org\/10.1016\/j.prrv.2025.05.001.","DOI":"10.1016\/j.prrv.2025.05.001"},{"key":"2750_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/pr.2014.82","volume":"76","author":"A El-Khuffash","year":"2014","unstructured":"El-Khuffash A, Jain A, Corcoran D, Shah PS, Hooper CW, Brown N, et al. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatr Res. 2014;76:238\u201344. https:\/\/doi.org\/10.1038\/pr.2014.82.","journal-title":"Pediatr Res"},{"key":"2750_CR24","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1055\/s-0039-3400316","volume":"9","author":"A Qasim","year":"2019","unstructured":"Qasim A, Jain SK, Aly AM. Antenatal magnesium sulfate exposure and hemodynamically significant patent ductus arteriosus in premature infants. AJP Rep. 2019;9:e353\u20136. https:\/\/doi.org\/10.1055\/s-0039-3400316.","journal-title":"AJP Rep"},{"key":"2750_CR25","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1055\/s-0044-1779620","volume":"41","author":"E Okulu","year":"2024","unstructured":"Okulu E, Kraja E, Kostekci YE, Seker E, Ozisik MS, Sar\u0131soy D, et al. Effect of antenatal magnesium sulfate exposure on patent ductus arteriosus in premature infants. Am J Perinatol. 2024;41:1665\u201372. https:\/\/doi.org\/10.1055\/s-0044-1779620.","journal-title":"Am J Perinatol"},{"key":"2750_CR26","doi-asserted-by":"publisher","first-page":"13877","DOI":"10.3390\/ijms232213877","volume":"23","author":"YJ Wei","year":"2022","unstructured":"Wei YJ, Hsu R, Lin YC, Wong TW, Kan CD, Wang JN. The association of patent ductus arteriosus with inflammation: a narrative review of the role of inflammatory biomarkers and treatment strategy in premature infants. IJMS. 2022;23:13877 https:\/\/doi.org\/10.3390\/ijms232213877.","journal-title":"IJMS"},{"key":"2750_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1056\/NEJM200009073431009","volume":"343","author":"RI Clyman","year":"2000","unstructured":"Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med. 2000;343:728\u201330. https:\/\/doi.org\/10.1056\/NEJM200009073431009.","journal-title":"N Engl J Med"},{"key":"2750_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000092870","volume":"89","author":"RI Clyman","year":"2006","unstructured":"Clyman RI. Mechanisms regulating the ductus arteriosus. Neonatology. 2006;89:330\u20135. https:\/\/doi.org\/10.1159\/000092870.","journal-title":"Neonatology"},{"key":"2750_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.605879","volume":"8","author":"C Liu","year":"2021","unstructured":"Liu C, Zhu X, Li D, Shi Y. Related factors of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Front Pediatr. 2021;8:605879. https:\/\/doi.org\/10.3389\/fped.2020.605879.","journal-title":"Front Pediatr"},{"key":"2750_CR30","unstructured":"Yeung MY. The underlying adrenal insufficiency in. World J Pediatr. 2006;1:8\u201313."},{"key":"2750_CR31","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41390-018-0006-z","volume":"84","author":"EL Shelton","year":"2018","unstructured":"Shelton EL, Waleh N, Plosa EJ, Benjamin JT, Milne GL, Hooper CW, et al. Effects of antenatal betamethasone on preterm human and mouse ductus arteriosus: comparison with baboon data. Pediatr Res. 2018;84:458\u201365. https:\/\/doi.org\/10.1038\/s41390-018-0006-z.","journal-title":"Pediatr Res"},{"key":"2750_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.siny.2018.02.006","volume":"23","author":"TR Lewis","year":"2018","unstructured":"Lewis TR, Shelton EL, Van Driest SL, Kannankeril PJ, Reese J. Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment. Semin Fetal Neonatal Med. 2018;23:232\u20138. https:\/\/doi.org\/10.1016\/j.siny.2018.02.006.","journal-title":"Semin Fetal Neonatal Med"},{"key":"2750_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025784","volume":"11","author":"CH Backes","year":"2022","unstructured":"Backes CH, Hill KD, Shelton EL, Slaughter JL, Lewis TR, Weisz DE, et al. Patent ductus arteriosus: a contemporary perspective for the pediatric and adult cardiac care provider. JAHA. 2022;11:e025784. https:\/\/doi.org\/10.1161\/JAHA.122.025784.","journal-title":"JAHA"},{"key":"2750_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1365-2125.2000.00231.x","volume":"50","author":"BJ Anderson","year":"2000","unstructured":"Anderson BJ, Woollard GA, Holford NHG. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Brit J Clin Pharma. 2000;50:125\u201334. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00231.x.","journal-title":"Brit J Clin Pharma"},{"key":"2750_CR35","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jama.2025.23330","volume":"335","author":"MM Laughon","year":"2026","unstructured":"Laughon MM, Thomas SM, Watterberg KL, Kennedy KA, Keszler M, Ambalavanan N, et al. Expectant management vs medication for patent ductus arteriosus in preterm infants: the PDA randomized clinical trial. JAMA. 2026;335:588 https:\/\/doi.org\/10.1001\/jama.2025.23330.","journal-title":"JAMA"},{"key":"2750_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jpeds.2018.09.012","volume":"205","author":"RI Clyman","year":"2019","unstructured":"Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, H\u00e5kansson S, et al. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr. 2019;205:41\u201348.e6. https:\/\/doi.org\/10.1016\/j.jpeds.2018.09.012.","journal-title":"J Pediatr"},{"key":"2750_CR37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa2305582","volume":"390","author":"S Gupta","year":"2024","unstructured":"Gupta S, Subhedar NV, Bell JL, Field D, Bowler U, Hutchison E, et al. Trial of selective early treatment of patent ductus arteriosus with ibuprofen. N Engl J Med. 2024;390:314\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2305582.","journal-title":"N Engl J Med"},{"key":"2750_CR38","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJMoa2207418","volume":"388","author":"T Hundscheid","year":"2023","unstructured":"Hundscheid T, Onland W, Kooi EMW, Vijlbrief DC, De Vries WB, Dijkman KP, et al. Expectant management or early ibuprofen for patent ductus arteriosus. N Engl J Med. 2023;388:980\u201390. https:\/\/doi.org\/10.1056\/NEJMoa2207418.","journal-title":"N Engl J Med"},{"key":"2750_CR39","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1055\/s-0040-1702945","volume":"10","author":"A Oshima","year":"2020","unstructured":"Oshima A, Matsumura S, Iwatani A, Morita M, Fujinuma S, Motojima Y, et al. Safety and feasibility of intravenous paracetamol for patent ductus arteriosus in indomethacin-\/ibuprofen-resistant or -contraindicated preterm infants: a case series. AJP Rep. 2020;10:e49\u201353. https:\/\/doi.org\/10.1055\/s-0040-1702945.","journal-title":"AJP Rep"},{"key":"2750_CR40","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1111\/bcp.15291","volume":"88","author":"DN Katsaras","year":"2022","unstructured":"Katsaras DN, Katsaras GN, Chatziravdeli VI, Papavasileiou GN, Touloupaki M, Mitsiakos G, et al. Comparative safety and efficacy of paracetamol versus non-steroidal anti-inflammatory agents in neonates with patent ductus arteriosus: A systematic review and meta-analysis of randomized controlled trials. Brit J Clin Pharma. 2022;88:3078\u2013100. https:\/\/doi.org\/10.1111\/bcp.15291.","journal-title":"Brit J Clin Pharma"}],"container-title":["Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02750-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02750-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02750-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T10:25:28Z","timestamp":1782123928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41372-026-02750-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":40,"alternative-id":["2750"],"URL":"https:\/\/doi.org\/10.1038\/s41372-026-02750-6","relation":{},"ISSN":["0743-8346","1476-5543"],"issn-type":[{"value":"0743-8346","type":"print"},{"value":"1476-5543","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved as a service evaluation by the governance department at both hospitals (UHB: CARMS-23417; ASPH: WHP 378). All methods were performed in accordance with the relevant guidelines and regulations. As this was a retrospective service evaluation using routinely collected clinical data, individual informed consent for participation was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}